Amer Sports logo

Amer Sports

AS | NYSE
Chart Builder DCF Calculator
$29.13
-$0.81 (-2.71%)
At close: Nov 16, 2026, 3:59 PM ET
$29.05
-$0.08 (-0.27%)
After-hours: Nov 16, 2026, 7:57 PM ET
-2.71%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
75.1
Fundamentals Excellent
Market Sentiment Neutral
Moat Narrow
Sector Rank #23/606 (Top 4%)

Key Statistics

Market Data

Market Cap $16.95B
1D Range
28.69 30.05
52W Range
26.27 41.96

Valuation (TTM)

PE 30.66
PB 2.47
EV/EBITDA 13.07

Valuation (NTM)

Forward PE 22.85
Forward PEG 0.72
Price Target $43.00
Loading financial charts...

Profile

Amer Sports, Inc. is a global enterprise dedicated to the creation, production, promotion, and sale of athletic equipment, clothing, footwear, and related accessories. The company's extensive reach co...

Industry Leisure
Employees 15,400
IPO Date Feb 1, 2024
Fiscal Year January - December

Latest News

Best Health & Fitness Stocks to Buy on Strong Market Potential

4 days ago · zacks.com

Best Health & Fitness Stocks to Buy on Strong Market Potential
Ahead of Amer Sports, Inc. (AS) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics

4 days ago · zacks.com

Ahead of Amer Sports, Inc. (AS) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
ASO or AS: Which Is the Better Value Stock Right Now?

6 days ago · zacks.com

ASO or AS: Which Is the Better Value Stock Right Now?
GE HealthCare reinforces leadership in AI with Lung Guidance and AutoAS on Vscan Air for point of care ultrasound assessments

14 days ago · gurufocus.com

GE HealthCare reinforces leadership in AI with Lung Guidance and AutoAS on Vscan Air for point of care ultrasound assessments
ASO vs. AS: Which Stock Is the Better Value Option?

27 days ago · zacks.com

ASO vs. AS: Which Stock Is the Better Value Option?
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

1 month ago · gurufocus.com

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
Amer Sports Chief Strategy Officer Exercises Options to Acquire More than $7 Million Shares. Is This a Signal to Buy AS?

1 month ago · fool.com

Amer Sports Chief Strategy Officer Exercises Options to Acquire More than $7 Million Shares. Is This a Signal to Buy AS?
New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

1 month ago · gurufocus.com

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress

2 months ago · gurufocus.com

AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis

2 months ago · gurufocus.com

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis

Earnings

Next Earnings
Nov 17, 2026
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
7
Consensus
Buy
Price Target
$43.00
Upside
+47.61%
Buy (7)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.